ATE500251T1 - Benzimidazole und ihre verwendung zur behandlung von diabetes - Google Patents
Benzimidazole und ihre verwendung zur behandlung von diabetesInfo
- Publication number
- ATE500251T1 ATE500251T1 AT07733082T AT07733082T ATE500251T1 AT E500251 T1 ATE500251 T1 AT E500251T1 AT 07733082 T AT07733082 T AT 07733082T AT 07733082 T AT07733082 T AT 07733082T AT E500251 T1 ATE500251 T1 AT E500251T1
- Authority
- AT
- Austria
- Prior art keywords
- phenyl
- benzimidazoles
- diabetes
- treatment
- dgat1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81189506P | 2006-06-08 | 2006-06-08 | |
PCT/GB2007/002070 WO2007141517A1 (en) | 2006-06-08 | 2007-06-06 | Benzimidazoles and their use for the treatemnt of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE500251T1 true ATE500251T1 (de) | 2011-03-15 |
Family
ID=38510308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07733082T ATE500251T1 (de) | 2006-06-08 | 2007-06-06 | Benzimidazole und ihre verwendung zur behandlung von diabetes |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090197926A1 (de) |
EP (1) | EP2035417B1 (de) |
JP (1) | JP2009539818A (de) |
KR (1) | KR20090016629A (de) |
CN (1) | CN101460492A (de) |
AT (1) | ATE500251T1 (de) |
AU (1) | AU2007255180B2 (de) |
CA (1) | CA2655225A1 (de) |
DE (1) | DE602007012875D1 (de) |
ES (1) | ES2359653T3 (de) |
HK (1) | HK1129099A1 (de) |
IL (1) | IL195912A0 (de) |
MX (1) | MX2008015725A (de) |
NO (1) | NO20085216L (de) |
NZ (1) | NZ573576A (de) |
WO (1) | WO2007141517A1 (de) |
ZA (1) | ZA200810643B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795283B2 (en) * | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
CN101346387A (zh) | 2005-12-22 | 2009-01-14 | 阿斯利康(瑞典)有限公司 | 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪 |
PL2004607T3 (pl) | 2006-03-31 | 2012-03-30 | Novartis Ag | Pochodne kwasu (4-(4-[6-(trifluorometylopirydyn-3-yloamino)-N-zawierające-heteroarylo]-fenylo)-cykloheksylo)-octowego i ich farmaceutyczne zastosowania |
EP2041099A1 (de) | 2006-05-30 | 2009-04-01 | AstraZeneca AB | 1,3,4-oxadiazolderivate als dgat1-inhibitoren |
CN101472905B (zh) | 2006-05-30 | 2011-12-14 | 阿斯利康(瑞典)有限公司 | 作为酰基辅酶甘油二酯酰基转移酶的抑制剂的取代的5-苯基氨基-1,3,4-噁二唑-2-基羰基氨基-4-苯氧基-环己烷甲酸 |
CN103641823A (zh) * | 2007-04-30 | 2014-03-19 | Abbvie公司 | 二酰甘油o-酰基转移酶1型酶的抑制剂 |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
KR20100099738A (ko) | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Dgat1 억제제로서의 카르바모일 화합물 190 |
WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
WO2010023609A1 (en) * | 2008-08-25 | 2010-03-04 | Piramal Life Sciences Limited | Oxazole, oxadiazole and thiazole derivatives as diacylglycerol acyltranferase inhibitors |
MX2011006672A (es) * | 2008-12-19 | 2011-07-20 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes. |
EP2805951B1 (de) | 2009-03-20 | 2018-03-14 | Metabasis Therapeutics, Inc. | Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon |
WO2010122968A1 (ja) | 2009-04-21 | 2010-10-28 | アステラス製薬株式会社 | ジアシルエチレンジアミン化合物 |
RU2011152517A (ru) | 2009-06-19 | 2013-07-27 | Астразенека Аб | Пиразинкарбоксамиды в качестве ингибиторов dgat1 |
TW201236685A (en) * | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
WO2023167545A1 (ko) * | 2022-03-04 | 2023-09-07 | 한국화학연구원 | 보호기가 도입된 폴리벤즈이미다졸, 이를 이용한 막의 제조방법 및 이의 용도 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017503A (en) * | 1975-06-12 | 1977-04-12 | Merck & Co., Inc. | Antifungal 1-substituted benzimidazoles |
US4983731A (en) * | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
US20030167483A1 (en) * | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
AU2856499A (en) * | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
DE60025830T2 (de) * | 1999-07-21 | 2006-11-02 | University Of Southern California, Los Angeles | Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung |
GB0021670D0 (en) * | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
EP1425014B1 (de) * | 2001-08-31 | 2006-12-13 | Sanofi-Aventis Deutschland GmbH | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren |
FR2840301B1 (fr) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
BR0312697A (pt) * | 2002-07-12 | 2005-04-26 | Aventis Pharma Gmbh | Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento |
JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
CN1753897A (zh) | 2002-11-22 | 2006-03-29 | 日本烟草产业株式会社 | 稠合双环含氮杂环 |
AR044152A1 (es) * | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
GB0325192D0 (en) * | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
CA2572874A1 (en) * | 2004-07-02 | 2006-01-12 | Sankyo Company Limited | Urea derivative |
JP2006083158A (ja) * | 2004-08-16 | 2006-03-30 | Sankyo Co Ltd | 置換されたウレア化合物 |
US7795283B2 (en) * | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
JPWO2006082952A1 (ja) * | 2005-02-01 | 2008-06-26 | 武田薬品工業株式会社 | アミド化合物 |
JP2008543747A (ja) * | 2005-06-11 | 2008-12-04 | アストラゼネカ アクチボラグ | Dgat阻害剤としてのオキサジアゾール誘導体 |
JP5076091B2 (ja) * | 2005-11-28 | 2012-11-21 | マドリガル・ファーマシューティカルズ・インコーポレーテッド | ジアシルグリセロールアシルトランスフェラーゼ(dgat)のインヒビター |
CN101346387A (zh) * | 2005-12-22 | 2009-01-14 | 阿斯利康(瑞典)有限公司 | 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪 |
EP2041099A1 (de) * | 2006-05-30 | 2009-04-01 | AstraZeneca AB | 1,3,4-oxadiazolderivate als dgat1-inhibitoren |
CN101472905B (zh) * | 2006-05-30 | 2011-12-14 | 阿斯利康(瑞典)有限公司 | 作为酰基辅酶甘油二酯酰基转移酶的抑制剂的取代的5-苯基氨基-1,3,4-噁二唑-2-基羰基氨基-4-苯氧基-环己烷甲酸 |
EP2035397A1 (de) * | 2006-06-06 | 2009-03-18 | Astra Zeneca AB | Chemische verbindungen |
GB0611507D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
US7569590B2 (en) * | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
KR20100099738A (ko) * | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Dgat1 억제제로서의 카르바모일 화합물 190 |
MX2011006672A (es) * | 2008-12-19 | 2011-07-20 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes. |
RU2011152517A (ru) * | 2009-06-19 | 2013-07-27 | Астразенека Аб | Пиразинкарбоксамиды в качестве ингибиторов dgat1 |
-
2007
- 2007-06-06 EP EP07733082A patent/EP2035417B1/de active Active
- 2007-06-06 MX MX2008015725A patent/MX2008015725A/es not_active Application Discontinuation
- 2007-06-06 WO PCT/GB2007/002070 patent/WO2007141517A1/en active Application Filing
- 2007-06-06 NZ NZ573576A patent/NZ573576A/en not_active IP Right Cessation
- 2007-06-06 KR KR1020097000116A patent/KR20090016629A/ko not_active Application Discontinuation
- 2007-06-06 ES ES07733082T patent/ES2359653T3/es active Active
- 2007-06-06 AU AU2007255180A patent/AU2007255180B2/en not_active Ceased
- 2007-06-06 US US12/303,512 patent/US20090197926A1/en not_active Abandoned
- 2007-06-06 AT AT07733082T patent/ATE500251T1/de not_active IP Right Cessation
- 2007-06-06 CA CA002655225A patent/CA2655225A1/en not_active Abandoned
- 2007-06-06 DE DE602007012875T patent/DE602007012875D1/de active Active
- 2007-06-06 CN CNA2007800210582A patent/CN101460492A/zh active Pending
- 2007-06-06 JP JP2009513759A patent/JP2009539818A/ja active Pending
-
2008
- 2008-12-14 IL IL195912A patent/IL195912A0/en unknown
- 2008-12-15 NO NO20085216A patent/NO20085216L/no not_active Application Discontinuation
- 2008-12-17 ZA ZA200810643A patent/ZA200810643B/xx unknown
-
2009
- 2009-07-20 HK HK09106593.9A patent/HK1129099A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL195912A0 (en) | 2011-08-01 |
WO2007141517A1 (en) | 2007-12-13 |
EP2035417A1 (de) | 2009-03-18 |
KR20090016629A (ko) | 2009-02-16 |
HK1129099A1 (en) | 2009-11-20 |
DE602007012875D1 (de) | 2011-04-14 |
MX2008015725A (es) | 2009-02-13 |
US20090197926A1 (en) | 2009-08-06 |
ZA200810643B (en) | 2010-05-26 |
NZ573576A (en) | 2011-01-28 |
EP2035417B1 (de) | 2011-03-02 |
JP2009539818A (ja) | 2009-11-19 |
CN101460492A (zh) | 2009-06-17 |
AU2007255180B2 (en) | 2011-02-03 |
NO20085216L (no) | 2009-01-06 |
ES2359653T3 (es) | 2011-05-25 |
CA2655225A1 (en) | 2007-12-13 |
AU2007255180A1 (en) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500251T1 (de) | Benzimidazole und ihre verwendung zur behandlung von diabetes | |
MX2008012404A (es) | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. | |
DE602007011446D1 (en) | Substituierte 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a-diacylglycerolacyltransferase | |
MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
MXPA05008619A (es) | Derivados novedosos de 2-piridincarboxamida. | |
MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
PE20130155A1 (es) | Derivados de ariletinilo | |
UY29486A1 (es) | Compuestos utiles en terapia | |
UA96947C2 (ru) | Производные циннамоил-пиперазина и их применение как антагонистов par-1 | |
CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
ME00680B (me) | Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže | |
PE20140716A1 (es) | Compuestos y su usos | |
ATE473221T1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus | |
NZ592314A (en) | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine | |
WO2008096769A1 (ja) | 置換されたセルコスポラミド誘導体を含有する医薬 | |
GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
ATE486058T1 (de) | Prolinamidderivate als nk3-antagonisten | |
PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
MX2012007836A (es) | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida. | |
SG154418A1 (en) | Granular composition and production thereof | |
BRPI0519485A2 (pt) | fenilpiperazin- e fenildiazepancarboxamidas aneladas contendo oxigÊnio como antagonistas d3 de dopamina | |
IL209732A0 (en) | Salicylamide derivatives as nicotinic alpha 7 modulators | |
EA200801910A1 (ru) | Новые гетероциклические циклоалкильные соединения, способ их получения и фармацевтические композиции, которые их содержат |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |